The National Institutes of Health halted a treatment arm of Bayer and Johnson & Johnson’s Xarelto in a phase 3 stroke prevention trial after an independent committee flagged safety concerns and a lack of efficacy. More: NIH stops Xarelto arm
read morePharmaEssentia will spend $46 million to build a manufacturing facility in Puerto Rico. The move forms part of the Taiwanese biotech’s global expansion strategy to support demand for its rare blood disease treatment, Besremi. More: Taiwan’s PharmaEssentia to build M
read moreWith Incyte set to lose patent protection for its blood cancer standout, Jakafi, in late 2028, the company will have to rely more on its topical cream, Opzelura. In its fourth full year on the market, the company reported that
read moreA batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. More: FDA untitled letters target
read moreThe agreement includes mRNA vaccine supply and a technology transfer that allows Mexico’s Laboratorios Liomont to produce Moderna’s 2025-2026 COVID vaccine. More: Moderna inks long-term pact with Mexico to bolster local mRNA vaccine supply Source: fierce
read more
Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease More: AstraZeneca bladder cancer therapy wins NICE backing Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals